

TABLE OF CONTENTS

PK/PD in Special Populations and Antimicrobial Prophylaxis I	1
PK/PD in Special Populations and Antimicrobial Prophylaxis I Panel	3
PK/PD in Critical Illness	
By Mohd Hafiz Abdul-Aziz, Ph.D., M.Clin Pharm, B.Pharm (Hons); and Jason A. Roberts, Ph.D., B.Pharm (Hons), B.App.Sc, FSHP, FISAC	
Introduction	7
Incidence of Sepsis and Septic Shock in Critically Ill Patients	8
Applying Clinical Pharmacology to Optimize Antimicrobial Use in Critically Ill Patients with Sepsis	9
Impact of Critical Illness on Antimicrobial PK	9
Altered Pathogen Susceptibility in ICU	14
PK/PD of Various Antibiotic Classes in Critically Ill Patients	15
Conclusion	20
References	23
Self-Assessment Questions	31
TDM of Anti-Infectives	
By Aaron M. Cook, Pharm.D., BCPS, BCCCP; and Melissa L. Thompson Bastin, Pharm.D., BCPS	
Introduction	35
Rationale for TDM	35
PK Variables	36
TDM Services	36
Antimicrobials	37
Antifungals	43
Conclusion	44
References	45
Self-Assessment Questions	48
PK/PD in Special Populations and Antimicrobial Prophylaxis II	53
PK/PD in Special Populations and Antimicrobial Prophylaxis II Panel	55
Surgical Prophylaxis	
By Emily Mui, Pharm.D., BCIDP; and Lina Meng, Pharm.D., BCCCP, BCIDP	
Basic Principles of Surgical Site Infection Prophylaxis in Adults	59
AP Considerations by Procedure	66
Conclusion	89
References	90
Self-Assessment Questions	102

Adult Vaccines

By Elias B. Chahine, Pharm.D., FCCP, FASCP, FFSHP, BCPS, BCIDP; and Allana J. Sucher, Pharm.D., BCPS, BCIDP

Vaccine-Preventable Diseases	107
Vaccine Types	110
Influenza Vaccines	111
Pneumococcal Vaccines	124
Herpes Zoster Vaccines	127
Tetanus, Diphtheria, and Pertussis Vaccines	127
Measles, Mumps, and Rubella Vaccine	129
Hepatitis A Vaccines	130
Hepatitis B Vaccines	130
Role of the Pharmacist in Addressing Pseudo-Science	131
Conclusion	131
References	132
Self-Assessment Questions	135

Drug Assay Methodologies

By Mohammad H. Al-Shaer, Pharm.D., Ph.D., BCPS; Charles A. Peloquin, Pharm.D., FCCP; and Gena M. Burch, Pharm.D., MS

Overview	139
Regulatory Standards/Requirements	141
General Procedures and Considerations for Drug Quantification in a Referral Laboratory	143
Conclusion	147
References	148
Self-Assessment Questions	149

PK/PD in Special Populations and Antimicrobial Prophylaxis III

PK/PD in Special Populations and Antimicrobial Prophylaxis III Panel	155
--	-----

Interactive Case: Clinical Decision Support Systems in Drug Dosing

By Ron Keizer, Pharm.D., Ph.D.; and Jonathan Falda, Pharm.D., BCPS

Interactive Case: Clinical Decision Support Systems and Their Role in Drug Dosing	159
Hyperlink to Activity	159
References	160
Self-Assessment Questions	161

Recorded Webcast: Regulatory Environment for Drugs

By Ravina Kullar, Pharm.D., MPH, FIDSA; and Mark J. Goldberger, M.D., MPH, FIDSA

Hyperlink to Activity	167
References	168
Self-Assessment Questions	169